The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.

ABSTRACT:

Background and aims

The composition of the human gut microbiota is linked to health and disease, and knowledge of the impact of therapeutics on the microbiota is essential to decipher their biological roles and to gain new mechanistic insights. Here we report the effect of aldafermin, an analog of the gut hormone FGF19, versus placebo on the gut microbiota in a prospective, phase 2 study in patients with NASH.

Approach and results

A total of 176 patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (nonalcoholic fatty liver disease activity score ≥ 4), fibrosis (F1-F3 by NASH Clinical Research Network criteria), and elevated liver fat content (≥ 8% by magnetic resonance imaging-proton density fat fraction) received 0.3 mg (n = 23), 1 mg (n = 49), 3 mg (n = 49),

SUBMITTER: Loomba R 

PROVIDER: S-EPMC7898628 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature